Amphista Therapeutics nabs $53m Series B

Amphista Therapeutics, a provider of next-generation targeted protein degradation solutions, has secured $53 million in Series B financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this